Drug Overview: Savaysa

Drug Overview: Savaysa

  • March 2018 •
  • 33 pages •
  • Report ID: 5391470 •
  • Format: PDF
Drug Overview
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Savaysa is also indicated for stroke prevention in atrial fibrillation.